drugset / Trial / NCT02154646

A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

NCT02154646

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety and side effects of LY2157299 in combination with gemcitabine in Japanese participants with pancreatic cancer that is advanced or has spread to another part of the body.

Timeline

Start
2014-05
Primary completion
2014-09
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Galunisertib Small molecule 150 mg Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous